VIIV HEALTHCARE PTY LTD

πŸ‡¦πŸ‡ΊAustralia
Ownership
-
Employees
-
Market Cap
-
Website

Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)

Phase 3
Recruiting
Conditions
Interventions
First Posted Date
2023-11-18
Last Posted Date
2024-12-17
Lead Sponsor
ViiV Healthcare
Target Recruit Count
3500
Registration Number
NCT06134362
Locations
πŸ‡ΉπŸ‡­

GSK Investigational Site, Pathum Wan, Thailand

A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1

Phase 2
Suspended
Conditions
Interventions
First Posted Date
2023-09-29
Last Posted Date
2024-10-01
Lead Sponsor
ViiV Healthcare
Target Recruit Count
26
Registration Number
NCT06061081
Locations
πŸ‡ͺπŸ‡Έ

GSK Investigational Site, Vitoria, Spain

Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults

First Posted Date
2023-09-15
Last Posted Date
2024-06-11
Lead Sponsor
ViiV Healthcare
Target Recruit Count
43
Registration Number
NCT06039579
Locations
πŸ‡¬πŸ‡§

GSK Investigational Site, London, United Kingdom

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult Participants

First Posted Date
2023-09-13
Last Posted Date
2024-07-10
Lead Sponsor
ViiV Healthcare
Target Recruit Count
48
Registration Number
NCT06033547
Locations
πŸ‡ΊπŸ‡Έ

GSK Investigational Site, Austin, Texas, United States

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2023-08-25
Last Posted Date
2024-01-25
Lead Sponsor
ViiV Healthcare
Target Recruit Count
160
Registration Number
NCT06012136
Locations
πŸ‡ΊπŸ‡Έ

GSK Investigational Site, Austin, Texas, United States

A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

First Posted Date
2023-08-18
Last Posted Date
2024-10-15
Lead Sponsor
ViiV Healthcare
Target Recruit Count
128
Registration Number
NCT05996471
Locations
πŸ‡΅πŸ‡·

GSK Investigational Site, San Juan, Puerto Rico

A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF

Phase 3
Active, not recruiting
Conditions
Interventions
First Posted Date
2023-06-22
Last Posted Date
2024-05-17
Lead Sponsor
ViiV Healthcare
Target Recruit Count
206
Registration Number
NCT05911360
Locations
πŸ‡¬πŸ‡§

GSK Investigational Site, Manchester, United Kingdom

A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants

First Posted Date
2023-06-09
Last Posted Date
2023-09-18
Lead Sponsor
ViiV Healthcare
Target Recruit Count
118
Registration Number
NCT05896761
Locations
πŸ‡ΈπŸ‡ͺ

GSK Investigational Site, Stockholm, Sweden

Β© Copyright 2024. All Rights Reserved by MedPath